Model-based Multichannel Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy: a Cross-over Study of Efficacy
The goal of this clinical trial is to to obtain a significant decrease in seizure frequency in patients with refractory focal epilepsy after applying treatment of cathodal tDCS, compared to sham stimulation drug-resistant epileptic patient. The main questions it aims to answer are: * Changes in quality of life * Percent of newly reported side effects after the stimulation period * Scores in epilepsy severity. Participants will be randomized in a cross-over, and will receive 10 days of tDCS or Sham. Each day will allow 2 periods of 20 minutes stimulation separated by 20 minutes off (with 40 minutes of cathodal stimulation total).
• Patient, parents or legal representative who have given written informed consent;
• Age: ≥ 9 years;
• Patients with drug-resistant focal epilepsy with no surgical indication or with a previous surgical failure, refusing surgery or with a planned surgery compatible with the total duration of this study;
• 4\) SEEG previously performed before inclusion with an adequate definition of the epileptogenic zone with all data required (pre-SEEG MRI, CT-scan or MRI with electrodes during SEEG and SEEG files) for personalization ;
• Patient having a pre-SEEG 3D-T1 MRI and CT-scan with electrodes during SEEG available;
• A research MRI scan that is suitable for navigated brain stimulation (NBS) and generation of electrical fields including dMRI for tractography;
• Number of seizures ≥3/month during the baseline (before the first session of tDCS treatment);
• Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment);
• Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out;
⁃ Patient able to understand, speak and write in French;
⁃ Patient able to follow study's procedure;
⁃ Patient beneficiary or affiliated to a health insurance plan.